MADRID and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical…
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA…
MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed…
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”)…
Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in…
Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with…
FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026HREC Approval Received…
Phare Audit Uses Proprietary Agentic AI to Maximize Earned Reimbursement, Enhancing R1’s Industry-Leading DRG-V with Full AuditabilityCHICAGO, Jan. 08, 2026…
PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem…
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small…